Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10067000 | 0.80 | TSHR (0.41) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL6277577 | 0.80 | SMN1; SMN2 (0.38) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL18099940 | 0.77 | TSHR (0.39) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL24829622 | 0.76 | TSHR (0.38) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL6037020 | 0.73 | SMN1; SMN2 (0.43) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL11507664 | 0.73 | TSHR (0.36) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL1012561 | 0.72 | SMN1; SMN2 (0.40) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL18932921 | 0.71 | ALDH1A1 (0.36) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL17787230 | 0.69 | ALDH1A1 (0.39) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 | |
| SCHEMBL5091798 | 0.69 | TSHR (0.44) | TSHRSMN1; SMN2RAB9AALDH1A1ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-02-05 | — | — | US | claimed |
| EP-4626462-A1 | GLUCOCEREBROSIDASE (GBA) POLYMER CONJUGATE, PREPARATION METHOD AND USE FOR NANOTECHNOLOGICAL BASED ENZYME REPLACEMENT THERAPY | Fundació Hospital Universitari Vall Hebron - Institut de Recerca (ES) | 2025-10-08 | — | — | EP | claimed |
| WO-2024115612-A1 | GLUCOCEREBROSIDASE (GBA) POLYMER CONJUGATE, PREPARATION METHOD AND USE FOR NANOTECHNOLOGICAL BASED ENZYME REPLACEMENT THERAPY | FUNDACIÓ HOSPITAL UNIVERSITARI VALL HEBRON - INSTITUT DE RECERCA (VHIR) (ES) | 2024-06-06 | — | — | WO | claimed |
| US-20230270882-A1 | PEPTIDE-NANOPARTICLE CONJUGATES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| US-11564995-B2 | Peptide-nanoparticle conjugates | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-01-31 | — | — | US | claimed |
| CN-115087465-A | Peptide-nanoparticle conjugates | 威斯康星校友研究基金会 | 2022-09-20 | — | — | CN | claimed |
| US-20210393799-A1 | DENDRITIC POLYMERS COMPLEXED WITH IMMUNE CHECKPOINT INHIBITORS FOR ENHANCED CANCER IMMUNOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2021-12-23 | — | — | US | claimed |
| CN-113613680-A | Dendrimers complexed with immune checkpoint inhibitors for enhancing cancer immunotherapy | 威斯康星校友研究基金会 | 2021-11-05 | — | — | CN | claimed |
| WO-2020092304-A9 | DENDRITIC POLYMERS COMPLEXED WITH IMMUNE CHECKPOINT INHIBITORS FOR ENHANCED CANCER IMMUNOTHERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2021-07-22 | — | — | WO | claimed |
| US-20210187120-A1 | PEPTIDE-NANOPARTICLE CONJUGATES | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2021-06-24 | — | — | US | claimed |
| JP-2011528106-A | — | — | 2011-11-10 | — | — | JP | claimed |
| EP-2054439-B1 | CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF | PASTEUR INSTITUT (FR) | 2011-06-01 | — | — | EP | claimed |
| EP-2318838-A1 | HIGH CAPACITY SOLID PHASE | Radiometer Medical ApS (DK) | 2011-05-11 | — | — | EP | claimed |
| US-20110015368-A1 | CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-01-20 | — | — | US | claimed |
| WO-2010006604-A1 | HIGH CAPACITY SOLID PHASE | RADIOMETER MEDICAL APS (DK) | 2010-01-21 | — | — | WO | claimed |
| EP-2054439-A1 | CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF | INSTITUT PASTEUR (FR) | 2009-05-06 | — | — | EP | claimed |
| WO-2008015273-A1 | CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF | INSTITUT PASTEUR (FR) | 2008-02-07 | — | — | WO | claimed |
| US-7067322-B2 | Fusion protein arrays on metal substrates for surface plasmon resonance imaging | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-06-27 | — | — | US | claimed |
| EP-0941738-B1 | Antigenic conjugates of conserved lipooligosaccharides of gram negative bacteria | WYETH CORP (US) | 2005-05-11 | — | — | EP | claimed |
| EP-0382781-B1 | COMPOSITION FOR TREATING CANCERS CHARACTERIZED BY OVER-EXPRESSION OF THE C-FMS PROTO-ONCOGENE | GENETICS INSTITUTE, INC. (US) | 1993-09-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015368-A1 | CD4-RECEPTOR-DERIVED PEPTIDES AND METHOD FOR THE PREPARATION THEREOF | CD4, GPR180, GPR65 | TSHR 1938/4885SMN1; SMN2 4518/4885RAB9A 4061/4885 |
| US-20260035410-A1 | THERAPEUTIC PEPTIDES AND METHODS OF PEPTIDE DESIGN | MICA, IGSF11, TNFSF10 | TSHR 165/4885SMN1; SMN2 1737/4885RAB9A 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.